首页> 外文期刊>Retina >One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
【24h】

One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.

机译:光动力疗法治疗中心性浆液性脉络膜视网膜病变后,脉络膜厚度为一年。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To retrospectively evaluate choroidal thickness 1 year after photodynamic therapy in eyes with central serous chorioretinopathy using optical coherence tomography. METHODS: Central serous chorioretinopathy was diagnosed using fluorescein angiography, and indocyanine green angiography was used to evaluate choroidal vascular hyperpermeability. We measured the subfoveal choroidal thickness using enhanced depth imaging optical coherence tomography. RESULTS: Thirteen eyes (13 patients; average age, 56.8 years) with central serous chorioretinopathy were observed 1 year after half-dose photodynamic therapy with verteporfin. The mean subfoveal choroidal thickness decreased significantly from 397 +/- 108 mum at baseline to 323 +/- 120 mum at 1 month, 312 +/- 117 mum at 3 months, 317 +/- 117 mum at 6 months, and 321 +/- 122 mum at 1 year (P < 0.01, for each comparison with baseline). However, the subfoveal choroid thickness significantly increased 2 days after photodynamic therapy to 441 +/- 120 (P < 0.01) compared with baseline. Central serous chorioretinopathy did not recur in any patient. Indocyanine green angiography images at 3 months showed less choroidal vascular hyperpermeability compared with baseline. CONCLUSION: Half-dose photodynamic therapy for central serous chorioretinopathy resulted in thinner subfoveal choroidal thickness 1 month after treatment, decreased the choroidal vascular hyperpermeability, and maintained the remission for 1 year. Enhanced depth imaging optical coherence tomography was helpful for monitoring the pathophysiologic choroidal changes in central serous chorioretinopathy.
机译:目的:使用光学相干断层扫描技术回顾性评估光动力疗法治疗中心性浆液性脉络膜视网膜病变眼后脉络膜厚度。方法:采用荧光素血管造影术诊断中央性浆液性脉络膜视网膜病变,并使用吲哚菁绿血管造影术评价脉络膜血管通透性。我们使用增强深度成像光学相干断层扫描技术测量了中央凹下脉络膜厚度。结果:半剂量光动力疗法联合维替泊芬治疗1年后观察到13眼(13例;平均年龄56.8岁)患有中央性浆液性脉络膜视网膜病变。平均中央凹下脉络膜厚度从基线时的397 +/- 108微米降至1个月的323 +/- 120微米,3个月的312 +/- 117微米,6个月的317 +/- 117微米和321 + /-1年时122妈(P <0.01,与基线的每次比较)。然而,与基线相比,光动力治疗后2天的小凹下脉络膜厚度显着增加至441 +/- 120(P <0.01)。中枢浆液性脉络膜视网膜病变未在任何患者中复发。与基线相比,3个月的吲哚菁绿血管造影图像显示脉络膜血管通透性较低。结论:半剂量光动力疗法治疗中心性浆液性脉络膜视网膜病变可导致治疗后1个月中央凹下脉络膜厚度变薄,脉络膜血管通透性降低,并维持1年缓解。增强的深度成像光学相干断层扫描有助于监测中央性浆液性脉络膜视网膜病变的病理生理脉络膜变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号